RGBP Reports Decline in Sellers; Strong Momentum f
Post# of 373
(Total Views: 506)
Posted On: 01/03/2019 10:21:16 AM
RGBP
Reports Decline in Sellers; Strong Momentum for Longs
Posted by Robert Shackelford on January 2, 2019 at 8:28 pm
https://cardinalweekly.com/regen-biopharma-in...for-longs/
Regen BioPharma, Inc. (OTCMKTS:RGBP) Logo
The stock of REGEN BIOPHARMA INC COMMON (OTCMKTS:RGBP) registered a decrease of 17.65% in short interest. RGBP’s total short interest was 18,200 shares in January as published by FINRA. Its down 17.65% from 22,100 shares, reported previously.
The stock increased 10.71% or $0.0003 during the last trading session, reaching $0.0031. About 2.72 million shares traded. Regen BioPharma, Inc. (OTCMKTS:RGBP) has 0.00% since January 2, 2018 and is . It has by 0.00% the S&P500.
Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. The company has market cap of $747,239. It intends to provide various products, including HemaXellerate I, a cellular therapy designed to heal damaged bone marrows; HemaXellerate II, a donor endothelial cell based therapeutic product; dCellVax, a gene silenced dendritic cell immunotherapy for the treatment of breast cancer; and NR2F6, a nuclear receptor cell line. It currently has negative earnings. The firm was founded in 2012 and is based in La Mesa, California.
More recent Regen BioPharma, Inc. (OTCMKTS:RGBP) news were published by: Seekingalpha.com which released: “Regen BioPharma identifies new class of product candidates – Seeking Alpha” on August 30, 2018. Also Seekingalpha.com published the news titled: “Regen Bio on go to start early-stage study of HemaXellerate in aplastic anemia – Seeking Alpha” on December 15, 2015. Seekingalpha.com‘s news article titled: “Regen Bio execs gets 10M-share payouts of preferred stock for resolving HemaXellerate clinical hold – Seeking Alpha” with publication date: April 11, 2016 was also an interesting one.
Posted by Robert Shackelford on January 2, 2019 at 8:28 pm
https://cardinalweekly.com/regen-biopharma-in...for-longs/
Regen BioPharma, Inc. (OTCMKTS:RGBP) Logo
The stock of REGEN BIOPHARMA INC COMMON (OTCMKTS:RGBP) registered a decrease of 17.65% in short interest. RGBP’s total short interest was 18,200 shares in January as published by FINRA. Its down 17.65% from 22,100 shares, reported previously.
The stock increased 10.71% or $0.0003 during the last trading session, reaching $0.0031. About 2.72 million shares traded. Regen BioPharma, Inc. (OTCMKTS:RGBP) has 0.00% since January 2, 2018 and is . It has by 0.00% the S&P500.
Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. The company has market cap of $747,239. It intends to provide various products, including HemaXellerate I, a cellular therapy designed to heal damaged bone marrows; HemaXellerate II, a donor endothelial cell based therapeutic product; dCellVax, a gene silenced dendritic cell immunotherapy for the treatment of breast cancer; and NR2F6, a nuclear receptor cell line. It currently has negative earnings. The firm was founded in 2012 and is based in La Mesa, California.
More recent Regen BioPharma, Inc. (OTCMKTS:RGBP) news were published by: Seekingalpha.com which released: “Regen BioPharma identifies new class of product candidates – Seeking Alpha” on August 30, 2018. Also Seekingalpha.com published the news titled: “Regen Bio on go to start early-stage study of HemaXellerate in aplastic anemia – Seeking Alpha” on December 15, 2015. Seekingalpha.com‘s news article titled: “Regen Bio execs gets 10M-share payouts of preferred stock for resolving HemaXellerate clinical hold – Seeking Alpha” with publication date: April 11, 2016 was also an interesting one.
(0)
(0)Regen BioPharma Inc (RGBPD) Stock Research Links
What I post is my opinion. Do your own DD. Make your own investment decision. Links, images, & retweets are not endorsements.
1️⃣I do not provide personal investment advice and I am not a qualified licensed investment advisor. I am an amateur investor.
2️⃣All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies.
3️⃣I will not and cannot be held liable for any actions you take as a result of anything you read here.
4️⃣Conduct your own due diligence, or consult a licensed financial advisor or broker before making any and all investment decisions. Any investments, trades, speculations, or decisions made on the basis of any information found on this site, expressed or implied herein, are committed at your own risk, financial or otherwise.
4️⃣Not Financial Advice. What I post is my opinion.
Also Paid for Advertising/IR/PR on Emerging Companies
Full Disclaimer: https://corporateads.com/disclaimer/
1️⃣I do not provide personal investment advice and I am not a qualified licensed investment advisor. I am an amateur investor.
2️⃣All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies.
3️⃣I will not and cannot be held liable for any actions you take as a result of anything you read here.
4️⃣Conduct your own due diligence, or consult a licensed financial advisor or broker before making any and all investment decisions. Any investments, trades, speculations, or decisions made on the basis of any information found on this site, expressed or implied herein, are committed at your own risk, financial or otherwise.
4️⃣Not Financial Advice. What I post is my opinion.
Also Paid for Advertising/IR/PR on Emerging Companies
Full Disclaimer: https://corporateads.com/disclaimer/